Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Jazz Pharmaceuticals plc JAZZ
$134.63
-$2.42 (-1.79%)
На 18:00, 12 мая 2023
+50.67%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
8848632083.00000000
-
week52high
163.31
-
week52low
125.36
-
Revenue
3659374000
-
P/E TTM
-41
-
Beta
0.74705800
-
EPS
-3.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 15:00
Описание компании
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Buy | Buy | 04 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| BMO Capital | Outperform | Outperform | 04 авг 2022 г. |
| UBS | Buy | 14 июн 2022 г. | |
| Goldman Sachs | Neutral | Neutral | 21 сент 2022 г. |
| Goldman Sachs | Neutral | Neutral | 29 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 10 ноя 2022 г. |
| Needham | Buy | Buy | 10 ноя 2022 г. |
| Goldman Sachs | Neutral | Neutral | 10 ноя 2022 г. |
| Goldman Sachs | Buy | Neutral | 09 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| COZADD BRUCE C | D | 367078 | 1000 | 01 февр 2023 г. |
| COZADD BRUCE C | D | 368078 | 2000 | 03 янв 2023 г. |
| COZADD BRUCE C | D | 370078 | 1000 | 03 янв 2023 г. |
| Pearce Samantha | D | 7438 | 531 | 03 янв 2023 г. |
| Pearce Samantha | D | 11309 | 531 | 03 янв 2023 г. |
| Pearce Samantha | A | 11840 | 531 | 03 янв 2023 г. |
| GALA RENEE D | D | 32558 | 2635 | 21 дек 2022 г. |
| Pearce Samantha | D | 7969 | 531 | 13 дек 2022 г. |
| Pearce Samantha | D | 11309 | 531 | 13 дек 2022 г. |
| Pearce Samantha | A | 11840 | 531 | 13 дек 2022 г. |
Новостная лента
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
Zacks Investment Research
11 мая 2023 г. в 13:44
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Jazz Pharmaceuticals PLC (JAZZ) Q1 2023 Earnings Call Transcript
Seeking Alpha
10 мая 2023 г. в 20:49
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President & COO Robert Iannone - EVP & Global Head, Research & Development Renee Gala - EVP & CFO Kim Sablich - EVP & GM, US Conference Call Participants Marc Goodman - SVB Securities Jason Gerberry - Bank of America Merrill Lynch Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gregory Fraser - Truist Securities Balaji Prasad - Barclays Bank Ashwani Verma - UBS Brandon Folkes - Cantor Fitzgerald & Co. Ami Fadia - Needham & Company David Amsellem - Piper Sandler & Co. Gregory Renza - RBC Capital Markets Madhu Kumar - Goldman Sachs Group Operator Good day, and thank you for standing by. Welcome to the Q1 2023 Jazz Pharmaceuticals Earnings Conference Call.
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
10 мая 2023 г. в 20:31
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Why Shares of Avadel Soared This Week
The Motley Fool
05 мая 2023 г. в 15:44
Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
PRNewsWire
19 апр 2023 г. в 07:45
Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful data results in idiopathic hypersomnia and essential tremor DUBLIN , April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston. "Our presence at the 2023 AAN Annual Meeting further reflects Jazz's scientific leadership in developing therapies for debilitating sleep disorders and rare epilepsy syndromes that advance treatment for people living with these conditions," said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.